NRNP 6540 MIDTERM EXAM LATEST 2023/NRNP6540 MIDTERM EXAM QUESTIONS AND ANSWERS (VERIFIED ANSWERS)|WALDEN UNIVERSITY

NRNP 6540 MIDTERM EXAM LATEST 2023/NRNP6540 MIDTERM EXAM QUESTIONS AND ANSWERS (VERIFIED ANSWERS)|WALDEN UNIVERSITY 1. When would the influenza vaccine be absolutely contraindicated? 2. You see a 69-year-old patient who recently moved to town and does not remember his last tetanus shot. What would you do? 3. E. D. is a 78-year-old woman who does not remember if she has ever had the immunization for herpes zoster. She does remember having chicken pox as a child. What would you recommend for her? Correct Answer: You could do one of two strategies: perform serologic testing for tetanus and diphtheria antitoxin to see if they are immune, or give one dose of Tdap, followed by Td at least 4 weeks later, followed by another dose of Td 6–12 months later. Tetanus/Tdap: In older adults, if the recommended childhood series was not done at all, the recommendation is one dose of Tdap, followed by Td at least 4 weeks later, followed by another dose of Td 6–12 months later. If vaccination documentation is incomplete, the provider can either consider serologic testing for tetanus and diphtheria antitoxin or assume that no vaccinations have been received and administer vaccine as directed above for patients who have not been vaccinated. 2 Correct Answer: Discuss the risks of herpes zoster and SE of vaccination with the patient and decide on whether to immunize. Herpes Zoster Recombinant zoster vaccine (RZV) was approved by the U.S. Food and Drug Administration in 2017 and recommended by the ACIP in 2017 for use in adults aged 50 years and older. RZV has a significantly higher efficacy than Zoster vaccine live ZVL, with rates of 90% to 97% for the prevention of herpes zoster and rates of 89% for prevention of PHN. Zoster vaccine live (ZVL) became available in 2006 and was recommended by the ACIP in 2008 for use in adults aged 60 years and older. It is a one-dose live attenuated strain of varicella zoster virus. ZVL has an overall vaccine efficacy of 49.1%. RZV is recommended by the ACIP to be given to adults aged 50 years or older. It is a two-dose vaccine series with the second dose given 2 to 6 months after the first. The ACIP recommends using RZV in preference to ZVL. Neither the Centers for Disease Control and Prevention (CDC) nor the World